Azide-PEG5-Tos | 236754-49-7
Catalog Number | R14-0191 |
Category | Azides |
Molecular Formula | C17H27N3O7S |
Molecular Weight | 417.48 |
Catalog Number | Size | Price | Quantity |
---|---|---|---|
R14-0191 | -- | $-- |
- Worldwide Delivery
- Quality Assurance
- 24/7 Customer Service
Product Introduction
Azide-PEG5-Tos is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
Chemical Information |
|
---|---|
Synonyms | 14-Azido-3,6,9,12-tetraoxatetradecyl 4-methylbenzenesulfonate |
Purity | >98.0% |
Shelf Life | ≥ 2 years |
IUPAC Name | 2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate |
Canonical SMILES | CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCCN=[N+]=[N-] |
InChI | InChI=1S/C17H27N3O7S/c1-16-2-4-17(5-3-16)28(21,22)27-15-14-26-13-12-25-11-10-24-9-8-23-7-6-19-20-18/h2-5H,6-15H2,1H3 |
InChI Key | RCRFPWKHJGMATE-UHFFFAOYSA-N |
Solubility | 10 mm in DMSO |
Appearance | Solid Power |
LogP | 0.88 |
- Product Specification
- Application
Storage | Store at -20 °C, keep in dry and avoid sunlight. |
Azide-PEG5-Tos is widely utilized in the field of bioconjugation, serving as a crucial component for linking biomolecules in a site-specific manner. Its unique azide group allows for the efficient attachment to various functional groups via click chemistry, particularly the Huisgen cycloaddition reaction with alkynes. This feature is especially advantageous in the synthesis of antibody-drug conjugates (ADCs), where precise conjugation is essential for maintaining the biological activity of the antibodies while enhancing the therapeutic efficacy of the drugs. By employing Azide-PEG5-Tos, researchers can achieve high specificity and yield in the formation of ADCs, facilitating the development of more effective cancer therapies.
Another significant application of Azide-PEG5-Tos lies in the realm of drug delivery systems. The PEGylation of therapeutic agents using this compound can improve their solubility and stability, prolonging their circulation time in the bloodstream. This is particularly important for hydrophobic drugs, which often face challenges related to bioavailability and toxicity. By incorporating Azide-PEG5-Tos into drug formulations, pharmaceutical scientists can create nanoparticles or liposomes that encapsulate the drug while simultaneously providing a stealth effect against the immune system. This enhances the therapeutic index of the drugs and reduces side effects, leading to better patient outcomes.
Azide-PEG5-Tos is also instrumental in the development of diagnostic tools, particularly in the area of imaging and biomarker detection. By conjugating this compound to imaging agents or probes, researchers can improve the targeting and localization of these agents within biological systems. For instance, the azide group allows for the covalent attachment of fluorophores or radiolabels to biomolecules, enhancing their visibility in various imaging modalities such as fluorescence microscopy or positron emission tomography (PET). This targeted approach not only improves the sensitivity of detection but also enables real-time monitoring of disease progression and treatment response.
Lastly, Azide-PEG5-Tos has applications in the creation of advanced biomaterials. The ability to functionalize surfaces with this compound allows for the development of smart materials that can respond to specific stimuli, such as changes in pH or temperature. By incorporating bioactive molecules or drugs onto the surface of these materials through the azide-PEG link, researchers can create systems that release therapeutic agents in a controlled manner. This is particularly valuable in tissue engineering and regenerative medicine, where spatial and temporal control over drug release is critical for promoting tissue repair and regeneration. The versatility of Azide-PEG5-Tos in crafting such innovative biomaterials holds great promise for future therapeutic strategies.
Computed Properties | |
---|---|
XLogP3 | 1.9 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 17 |
Exact Mass | 417.15697138 g/mol |
Monoisotopic Mass | 417.15697138 g/mol |
Topological Polar Surface Area | 103Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 527 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently-Bonded Unit Count | 1 |
Compound Is Canonicalized | Yes |
Patents
Publication Number | Title | Priority Date |
---|---|---|
WO-2022056273-A1 | Lipid conjugates for the delivery of therapeutic agents | 2020-09-11 |
WO-2020113233-A1 | Irak degraders and uses thereof | 2018-11-30 |
AU-2019389174-A1 | Irak degraders and uses thereof | 2018-11-30 |
BR-112021010484-A2 | Irak degraders and their uses | 2018-11-30 |
CN-113423427-A | IRAK degraders and their uses | 2018-11-30 |
Applications of Fluorescent Probes & Dyes
Get More Product Details?
Related Products